ArticleAvicenna journal of phytomedicine2026
Herbal adjuvant therapy with a combination of Green Tea, Persian Borage, and Purslane to reduce antipsychotic-induced weight gain in Schizophrenia: A randomized controlled trial.
Article in Avicenna journal of phytomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Second-generation antipsychotics can lead to metabolic problems. This study investigated whether an herbal compound with green tea, Persian borage, and purslane extracts could help in antipsychotic-induced weight management in schizophrenia patients. Materials and Methods: This triple-blind, placebo-controlled study at Hijazi Psychiatry Hospital in Mashhad, Iran, involved 73 schizophrenia patients. Participants received either an herbal compound or a placebo, alongside their antipsychotic medication. The primary outcome was changes in body mass index (BMI), with secondary outcomes including waist-to-hip ratio (WHR), fasting blood sugar (FBS), HbA1c, lipid profile, blood pressure, appetite, quality of life, and psychotic symptom severity. Results: The herbal compound significantly reduced BMI (p<0.001), WHR (p<0.001), HbA1c (p=0.042), low-density lipoprotein (LDL) concentration (p=0.009), and systolic blood pressure (p=0.015) compared to the placebo. No significant differences were observed in FBS or lipid profile (except LDL) between the two groups. The intervention group had significantly lower appetite levels than the placebo group at weeks four and eight (p=0.001). There was no significant difference between the two groups in the Positive and Negative Syndrome Scale (PANSS) score at any time. Participants reported no serious adverse effects. Conclusion: Adding herbal compound to antipsychotics significantly lowered BMI, WHR, HbA1c, LDL levels, systolic blood pressure, and appetite in schizophrenia patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.